

Apremilast Pediatric Study in Children With Active Juvenile Psoriatic Arthritis

NCT04804553

Status	RECRUITING
Phase	Phase 3
Sponsor	Amgen
Enrollment	60 participants

Key Eligibility Criteria

Inclusion (9)

- Male or Female participants 5 to < 18 years of age at the time of randomization.
- Participant must have a confirmed diagnosis of juvenile psoriatic arthritis (JPsA) according to the International League of Associations for Rheumatology (ILAR) Edmonton Revision (Petty, 2001) classification criteria of at least 6 months duration:
- Arthritis and psoriasis, OR
- Arthritis with at least 2 of the following:
- Dactylitis
- ... and 4 more (see full listing online)

Exclusion (7)

- Exclusions per ILAR Edmonton Revision (Edmonton, 2001) criteria for JPsA include:
- Arthritis in an HLA-B27-positive male with arthritis onset after 6 years of age
- Ankylosing spondylitis, sacroiliitis with inflammatory bowel disease, Reiter's syndrome, acute anterior uveitis, or a history of one of these disorders in a first-degree relative
- History of IgM rheumatoid factor on at least 2 occasions at least 3 months apart
- Presence of systemic juvenile idiopathic arthritis (JIA).
- ... and 2 more (see full listing online)

Locations (45 total)

Landeskrankenhaus Bregenz, Bregenz, Austria
Universitair Ziekenhuis Gent, Ghent, Belgium
Centre Hospitalier Regional de la Citadelle, Liège, Belgium
... and 42 more locations

<https://clinicaltrials.gov/study/NCT04804553>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at ClinicalTrials.gov. Generated by ClinicalTrialsFinder.org.